Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

NBA Hall of Famer Earvin “Magic” Johnson is investing in a pharmacy startup that helps clinics with high volumes of HIV ...

Researchers looked at 198 kidney transplants performed at hospitals across the United States. They found similar results ...

The availability of such kidney transplants outside of the research setting could substantially improve organ availability ...

A new study found people with HIV can safely receive donated kidneys from deceased donors with the virus. According to ...

in combination with an optimized background regimen in people with multi-drug resistant HIV. HIV prevention data will include an analysis of newly initiated pre-exposure prophylaxis (PrEP ...

Gilead's partnership with generic manufacturers to lower the cost of its HIV drug lenacapavir is criticized for being too restrictive. Key countries with rising HIV rates are excluded, and the ...

Gilead Sciences has announced that cheaper versions of its “gamechanger” HIV prevention drug, lenacapavir, will be made available in 120 low and middle income countries. Lenacapavir is an ...

Faster access to HIV drug lenacapavir in India hinges on the waiver of local clinical trials. Six companies, including three from India, have non-exclusive, royalty-free licenses to produce generic ...

Indian pharmaceutical companies are set to produce generic versions of lenacapavir, an HIV prevention drug, under agreements with US-based Gilead Sciences to distribute it in 120 resource-limited ...

This week, we heard that six generic drug companies have signed voluntary licensing deals to make the HIV prevention injection ... countries not on Gilead’s list of 120. It’s an old Gilead ...